PKCα-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-β1

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Chen, Ying ^a   Yu, Guanzhen ^b   Yu, Danghui ^a   Zhu, Minghua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C ALPHA INHIBITOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ARTICLE; CANCER CELL; CELL VIABILITY; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; APOPTOSIS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; IMAGE SUBTRACTION; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; PANCREATIC NEOPLASMS; PROTEIN KINASE C-ALPHA; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SUBTRACTION TECHNIQUE; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 77955191504     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-104     Document Type: Article

References (43)

1. Potent induction of human colon cancer uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-blycoprotein-independent mechanism. PJ Bergman KR Gravitt NE Ward, et al. Invest New Drugs 1997 15 311 318 10.1023/A:1005933401603 9547673
2. Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. KR Gravitt NE Ward D Fan, et al. Biochem Phamacol 1994 48 375 381 10.1016/0006-2952(94)90110-4 (Pubitemid 24243981)
3. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. S Anuchapreeda P Thanarattanakom S Sittipreechacham, et al. Arch Pharm Res 2006 29 866 873 10.1007/BF02973907 17121181 (Pubitemid 44808452)
4. Development and validation of a phosphorylated SMAD ex vivo stimulation assay. DL Famington JM Yingling JA fill, et al. Biomarker 2007 12 313 330 10.1080/13547500601162441 (Pubitemid 46681033)
5. Tumor microenvironment: hypoxia and buffer capacity for immunotherapy. C Liu S Gao Z Qu, et al. Med Hypotheses 2007 69 590 595 10.1016/j.mehy.2006.12.053 17360127
6. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. YA Yoo YH Kim JS Kim, et al. Bichim biophys Acta 2008 1783 438 447 10.1016/j.bbamcr.2007.12.001
7. Role of TGF beta in the anti-estrogen response/resistance of human breast cancer. JR Benson M Baum AA Colletta, J Mammary Gland Biol Neoplasia 1996 1 381 389 10.1007/BF02017394 10887512
8. Inhibition of TGFbeta signaling in cancer therapy. CL Arteaga, Curr Opin Genet Dev 2006 16 30 37 10.1016/j.gde.2005.12.009 16377175
9. Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. G Wilding, Cancer Surv 1991 11 147 163 10.3167/ 001115799782483762 1841749
10. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. VC Liu LY Wong T Jang, et al. J Immunol 2007 178 2883 2892 17312132
11. Induction of p21waf1 expression and growth inhibiton by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. AM Grau L Zhang W Wang, et al. Cancer Res 1997 57 3929 3934 9307274
12. Expression of Smad proteins in human colorectal cancer. O Korchynskyi M Landstrom R Stoika, et al. Int J Cancer 1999 82 197 202 10.1002/(SICI)1097- 0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V 10389752
13. Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuateds proliferation without altering angiogenesis. M Yasutome J Gunn M Korc, Clin Exp Metastasis 2005 22 461 473 10.1007/s10585-005-2891-x 16320109
14. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. B Peng JB Fleming T Breslin, et al. Clin Cancer Res 2002 8 3628 3638 12429655
15. TGF-beta signaling and androgen receptor status determine apoptotis cross-talk in human prostate cancer cells. ML Zhu JV Partin EM Bruckheimer, et al. Prostate 2008 68 287 295 10.1002/pros.20698 18163430
16. Smad4-independent TGF-beta signaling in tumor cell migration. K Giehl Y Imamichi A Menke, Cells Tissues Organs 2007 185 123 130 10.1159/000101313 17587818
17. Over-expression of TGF-beta1 in Smad4-deficient human oral carcinoma cells causes tumor regression in vivo by mechanisms that sensitize cells to apoptosis. S Thavaraj Ic Paterson A Hagur, et al. J Pathol 2006 2005 14 20
18. Smad4 silencing in pancretic cancer lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. A Jazag H Ijichi F Kanai, et al. Oncogen 2005 24 662 671 10.1038/sj.onc.1208102 (Pubitemid 40188570)
19. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. H Ijichi M Otsuka K Tateishi, et al. Oncogen 2004 23 1043 1051 10.1038/sj.onc.1207222 (Pubitemid 38269958)
20. sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. HM Warenius LA Seabra P Maw, Int J Cancer 1996 67 224 231 10.1002/(SICI)1097-0215(19960717)67: 2<224::AID-IJC13>3.0.CO;2-B 8760592
21. p21Waf1/Clip1 act in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Y Zhang N Fujita T Tsuruo, Int J Cancer 1999 83 790 797 10.1002/(SICI)1097-0215(19991210)83:6<790::AID- IJC15>3.0.CO;2-6 10597196
22. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MARK/mitochondrial pathway. WL Zhuo Y Wang XL Zhuo, et al. Biochem Biophys Res Commun 2008 369 1098 1102 10.1016/j.bbrc.2008.02.143 18331824
23. Chemical synthesis and biological properties of novel fluorescent antifolates in Pgp- an MRP-overexpressing tumor cell lines. C Robson KA Wright PR Twentyman, et al. Biochem Phamacol 1998 56 807 816 10.1016/S0006-2952(98) 00068-9 (Pubitemid 28458974)
24. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: Role of EGF receptor ligands. G Del castillo MM Murillo A Alvarez-Bamientos, et al. Exp Cell Res 2006 312 ;2860 2871 10.1016/j.yexcr.2006.05.017 16828470
25. Protein kinase C alpha expression in breast and ovarian cancer. M Lahn G Kohler K Sundel, et al. Oncology 2004 67 1 10 10.1159/000080279 15459489 (Pubitemid 39370344)
26. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. S Scala B Dickstein J Regis, et al. Clin Cancer Res 1995 1 1581 1587 9815959
27. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. GC Blobe CW Sachs WA Khan, et al. J Biol Chem 1993 268 658 664 8093247
28. Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells. D Ratnasinghe JM Phang GC Yeh, Int J Oncol 1998 13 79 84 9625806
29. P-glycoprotein, multidrug resistance and protein kinase C. RL Fine TC Chambers CW Sachs, Stem cells 1996 14 47 55 10.1002/stem.140047 8820951
30. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. LW Feurino WE Fisher U Bharadwaj, et al. Cancer Invest 2006 24 696 703 10.1080/07357900600981398 17118780
31. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. S Roy E Kenny S Kennedy, et al. Anticancer Res 2007 27 1325 1330 17593626
32. Preparation and characterization of polyclonal antibodies against ARL-1 protein. Jf Jin LD Yuan L Liu, et al. World J Gastroenterol 2003 9 1455 1459 12854140
33. The molecular basis of differential subcellular localization of C2 domains of protein kinase C-alpha and group Iva cytosolic phospholipase A2. RV Stahelin JD Rafter S Das, et al. J Biol Chem 2003 278 12452 12460 10.1074/jbc.M212864200 12531893
34. Induction and subcellular localization of protein kinase C isozymes following renal ischemia. BJ Padanilam, Kidney Int 2001 59 1789 1797 10.1046/j.1523-1755.2001.0590051789.x 11318949
35. Unique phosphorylation of protein kinase C-alpha in PC12 cells induces resistance to translocation and down-regulation. A Gatti PJ Robinson, J Biol Chem 1996 271 31718 31722 10.1074/jbc.271.49.31718 8940195
36. Expression, subcellular distribution and response to phorbo esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. BA Cloud-Heflin RA McMasters MT Osbom, et al. Eur J Biochem 1996 239 796 804 10.1111/j.1432-1033.1996.0796u. x 8774728
37. Transforming growth factor-beta1 inhibits membrane association of protein kinase C alpha in a human prostate cancer cell line, PC3. ML Lamm DD Long SM Goodwin, et al. Endocrinology 1997 138 4657 4664 10.1210/en.138.11.4657 9348191
38. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha acitivation in pancreatic cancer cells. JY Chow H Dong KT Quach, et al. Am J Physiol Gastrointest Liver Physiol 2008 294 899 905 10.1152/ajpgi.00411.2007 18239055
39. Sre phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MARK during breast cancer cell proliferation and invaion. AJ Galliher WP Schiemann, Cancer Res 2007 67 3752 3758 10.1158/0008-5472.CAN-06-3851 17440088
40. TGF-beta receptor-activated p38 MARK kinase mediates Smad-independent TGF-beta responses. L Yu MC Hebert YE Zhang, Embo J 2002 21 3749 3759 10.1093/emboj/cdf366 12110587
41. Transforming growth factor beta 1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. V Ellenrieder SF Hendler W Boeck, et al. Cancer Res 2001 61 4222 4228 11358848
42. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13- acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. S Isonishi K Ohkawa T Tanaka, et al. Br J Cancer 2000 82 34 38 10.1054/bjoc.1999.0873 10638963
43. Protein kinase C inhibitor Go6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. L Qamar R Davis A Anwar K Behbakht, Gynecol Oncol 2008 11 425 431 10.1016/j.ygyno.2008.04.039